Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies by Hans-Peter Hartung et al.
RESEARCH Open Access
Variability in detection and quantification of
interferon β-1b–induced neutralizing antibodies
Hans-Peter Hartung1,12*, Bernd Kieseier1, Douglas S Goodin2, Barry GW Arnason3, Giancarlo Comi4, Stuart Cook5,
Massimo Filippi4, Douglas R Jeffery6, Ludwig Kappos7, Timon Bogumil8, Brigitte Stemper9, Rupert Sandbrink1,9,
Yukiko Nakada10, Haruhiko Nakajima10, Susanne Schwenke9, Stephan Lehr9, Jürgen Heubach9,
Christoph Pohl9,11 and Joachim Reischl9
Abstract
Background: Interferon-beta (IFNB) therapy for multiple sclerosis can lead to the induction of neutralizing
antibodies (NAbs) against IFNB. Various methods are used for detection and quantification of NAbs.
Methods: Blood samples from 125 IFNB-1b–treated patients, which were tested NAb negative or NAb positive after
conclusion of a clinical study, were retested three years after first being assessed in four different laboratories that
offer routine NAb testing to practicing neurologists. The myxovirus protein A (MxA) induction assay, the cytopathic
effect (CPE) assay (two laboratories), or the luciferase assay were used. Intra- and inter-laboratory agreement
between assays with respect to NAb detection and NAb titer quantification were evaluated.
Results: High agreement for NAb detection (kappa coefficient, 0.86) and for titer levels was observed for the intra-
laboratory comparison in the laboratory using the MxA induction assay performed three years ago and now. A
similarly high agreement for NAb detection (kappa coefficient, 0.87) and for titer quantification was noted for the
MxA assay of this laboratory with one of two laboratories using the CPE assay. All other inter-laboratory
comparisons showed kappa values between 0.57 and 0.68 and remarkable differences in individual titer levels.
Conclusions: There are considerable differences in the detection and quantification of IFNB-induced NAbs among
laboratories offering NAb testing for clinical practice using different assay methods. It is important that these
differences are considered when interpreting NAb results for clinical decision-making and when developing general
recommendations for potentially clinically meaningful NAb titer levels.
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Introduction
Up to 40% of people with multiple sclerosis (MS) treated
with interferon-β (IFNB) develop IFNB neutralizing anti-
bodies (NAbs) [1]. Anti-IFNB NAbs have been associated
with reduced therapeutic efficacy [2] exemplified by an
increased annualized relapse rate and increased disease ac-
tivity on brain magnetic resonance imaging. Furthermore,
in-vitro studies have demonstrated that NAbs can lead to
alterations in the transcription rate of MS-relevant genes
[3,4]. In contrast, other studies have indicated that the re-
lapse rate is not significantly different between NAb-
negative and NAb-positive patients [2]. Generally, the fre-
quency of NAbs against IFNB diminishes over time, and
especially patients who develop NAbs to IFNB-1b (Beta-
feronW, Chiron Corporation, Emeryville, CA, USA) often
revert to NAb-negative status upon subsequent testing [5-
9]. High NAb titers appear to be more persistent and thus
may have a greater impact on the efficacy of IFNB-1b
[2,10,11].
Part of the inconsistent findings with regard to the clin-
ical relevance of NAbs might result from the fact that vari-
ous methods are used for evaluating NAbs in MS patients
treated with IFNB and that IFNB-1a and -1b–treated
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patients are assessed jointly in some studies on NAbs. The
objective of this study was to compare NAb detection and
quantification of NAb titers in laboratories offering NAb
testing for treatment decision making in clinical routine.
These laboratories use different assay methods, that is, the
myxovirus protein A (MxA) induction assay and the cyto-
pathic effect (CPE) assay [1,2,12].
Methods
Study design
Blood samples obtained in the Betaferon Efficacy Yield-
ing Outcomes of a New Dose (BEYOND) study were
used. The BEYOND study was a randomized, parallel
group, Phase 3 study conducted across 198 centers in 26
countries worldwide [13]. In total, 2,244 patients with
relapsing-remitting MS were enrolled and randomly
assigned in a ratio of 2:2:1 to receive one of two doses of
IFNB-1b (either 250 μg or 500 μg) subcutaneously every
other day or 20 mg glatiramer acetate subcutaneously
every day. Serum samples for NAb testing were collected
at baseline and then every six months under treatment.
At the end of the study, these samples were tested for
NAb positivity and for NAb titer quantification with an
MxA induction assay. A sample was considered “NAb
positive” with a titer of at least 20 units (lower limit of
quantification, LLOQ) using this assay. If no quantifiable
NAb titer is detectable, the respective sample was con-
sidered “NAb negative.” Comprehensive details of the
measurement, quantification and NAb titers in the BE-
YOND study have been reported previously [14]. The In-
stitutional Review Boards of all participating centres
approved the study protocol and all patients gave written
informed consent before trial entry.
The present study used serum samples of the BE-
YOND study. Of serum samples obtained 1.5 years after
the start of IFNB-1b 250 μg treatment, 125 were selected
for the intra- and inter-laboratory comparison based on
the original test results from Laboratory A (A(I)). Sample
selection was not representative of the NAb status distri-
bution nor of NAb titers observed in the BEYOND trial,
but optimized for dense and steady coverage of the en-
tire NAb titer range (n = 82) while including enough
NAb-negative samples (n = 43). The samples had been
stored at −20° and thawed and frozen once during ali-
quoting. Three years after the original NAb analysis,
sample aliquots were reanalyzed at Laboratory A using
the same MxA induction assay (A[II]). In addition, the
aliquots were tested in three other laboratories using the
CPE bioassay (Laboratories B, LLOQ=8, and C, LLOQ=
20) and the luciferase bioassay in Laboratory D (LLOQ=
20). There was no upper limit of quantification for La-
boratories A and B, but it was 640 for the CPE assay per-
formed at Laboratory C and 1,202 for the luciferase
assay of Laboratory D. The principles of NAb testing
using these three bioassays have been published previ-
ously [15-19].
All of the laboratories that assayed the samples for
neutralizing antibody activity in this study offer neutral-
izing antibody testing in clinical practice, but it was
agreed that they would remain anonymous when report-
ing the results of this study. The ability of neutralizing
antibodies to block the biological activity of IFNB, which
is dependent on the molecule binding to its receptor, is
measured in neutralization assays. In the MxA assay,
serum samples were mixed with IFNB-1b and incubated
with A549 cells (human embryonic lung cells) [13]. Cell
lysates were then tested for MxA protein using ELISA.
The neutralizing titer was the reciprocal serum dilution
that reduced the MxA-inducing activity 10-fold. At the
end of the BEYOND study and after storage for three
years, the samples were tested by Rentschler, Laupheim,
Germany.
In the luciferase assay, HL116 cells stably transfected
with a luciferase reporter gene cassette were used, as
described before [18]. Briefly, a transcellular signaling
mechanism is activated when the IFNB molecule binds
to its receptor, which activates the IFN-stimulated re-
sponse element. This translocates to the nucleus where it
causes the transcription of the luciferase gene; the result-
ing luminescence signal was read by a conventional
reader. The amount of luciferase produced in response
to a known quantity is predictable, but this response is
blocked by neutralizing antibody. IFNB-1a was used in
this assay.
A number of CPE assays have been developed using a
variety of cell lines and viruses to determine the titer of
an IFN sample. The addition of neutralizing antibodies
to the interferon allows the titer of neutralizing antibody
to be quantified. Many of these assays provide a rapid,
simple and sensitive assay. The CPE assay reported
under laboratory B was performed by the Mitsubishi
Chemical Medience Corporation (Tokyo, Japan) using
FL cells and Sindbis virus. IFNB-1b was used in this
assay. The IFN used in the CPE assay performed by la-
boratory C was not specified. No details about the assay
were provided and the laboratory did not agree to dis-
close its identity for this publication.
Statistical analyses
Patient samples with NAb titers below the LLOQ are
defined as being NAb negative, and samples with quanti-
fiable NAb titers as being NAb positive. The agreement
between the different bioassays regarding NAb negative
versus NAb positive status was assessed using the kappa
coefficient. The kappa coefficient is commonly used in
studies that measure agreement between two or more
observations, since it accounts for the fact that observers
will occasionally agree purely by chance [20]. A kappa of
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0 indicates agreement by chance, whereas a kappa of 1
indicates perfect agreement [20]. Titer values were com-
pared graphically by means of scatter plots.
Results
Distribution of NAb titers reported by different
laboratories
The titer levels reported by the different laboratories are
shown in Figure 1. The median values were comparable
in the original analysis (52) and in the reanalysis after
three years (49) performed at Laboratory A, and in the
analysis performed at Laboratory C (50). Median levels
were lower in Laboratory B (15.3) and higher in Labora-
tory D (162). The maximum titers observed were in the
same order of magnitude in Laboratories A (5,646) and
B (2,180), but censored in the analysis at Laboratories C
(640; n = 18 samples) and D (1,202; n = 44 samples). The
percentage of samples below the laboratory-specific
LLOQs ranged from 27% (Laboratory D) to 44% (La-
boratory B).
Intra- and inter-laboratory comparison of NAb titer values
For the intra-laboratory comparison we assessed the
agreement between the repeat NAb titer measurements
at Laboratory A (Figure 2). All 43 samples with NAb
titers below the LLOQ in the original analysis were con-
firmed in the reanalysis three years later. In addition,
eight samples with low NAb titers in the original analysis
yielded NAb titers below the LLOQ in the reanalysis. For
the 74 samples with titer levels above the LLOQ in both
laboratory runs, there was a high level of agreement
across the entire range of titer levels.
Inter-laboratory comparisons are shown in Figure 3 in a
similar fashion. Figure 3a demonstrates that NAb titer
levels resulting from Laboratory B were systematically
lower than values determined at Laboratory A. The NAb
titer values, however, were strongly correlated, despite the
different NAb assay technologies applied (MxA induction
assay at Laboratory A vs. CPE assay at Laboratory B). The
correlation of NAb titers was much weaker when compar-
ing the results from Laboratories B and C, which both ap-
plied the CPE assay principle (Figure 3d). Despite similar
median NAb titer values in Laboratories A and C, the titer
correlation was weak as well (Figure 3b). In comparison
with all other laboratories, Laboratory D reported a rela-
tively large number of samples with titer values above the
LLOQ (Figure 3c, e and f). For samples with quantifiable
NAb titers in comparisons involving Laboratory D, titer
values tended to be higher in Laboratory D, and the corre-
lations were weak.
Consistency of NAb test results across laboratories
The agreement regarding the NAb status result (posi-
tive vs. negative) within Laboratory A and between labora-
tories is provided as kappa values in Table 1. The retest










































Figure 1 Scatter plot of reported titer levels. The number of valid results out of the 125 provided samples is given below each laboratory
identifier. The gray bar indicates the median value, the black bar indicates the lower limit of quantification (LLOQ). Laboratories C and D had an
upper limit of quantification, that is, values are censored. NAb=neutralizing antibody.
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indicating an almost perfect agreement. This kappa value
was even slightly exceeded for the NAb status compari-
sons in Laboratory A and Laboratory B, with a calculated
kappa value of 0.87. The kappa values for the other inter-
laboratory comparisons ranged from 0.57 to 0.68.
Special attention was paid to the question of whether a
patient was consistently classified as being NAb positive or
NAb negative by the four different laboratories, as this
may have implications for further treatment. Figure 4
shows that, from the samples selected for this laboratory
comparison, 22% were consistently reported as NAb
negative and 48% were consistently reported as NAb
positive. However, for about one-third of the samples
(30%), the four laboratories involved reported inconsist-
ent results regarding a patient´s NAb status.
Discussion
Recently, an international panel of MS experts on NAbs
to IFNB therapy convened under the auspices of the
Neutralizing Antibodies on Interferon beta in Multiple
Sclerosis consortium (NAbinMS: a collaborative project
funded by the European Union) and issued recommen-
dations for clinical use of data on NAb to IFNB therapy
[21]. In this position paper, the use of the MxA induction
assay is suggested to test neutralizing activity to IFNB
therapy and a switch to a non-IFNB therapy is recom-
mended in cases of sustained high-titer NAb positivity
and/or lack of IFNB bioactivity. However, in clinical
practice, other assays are also employed to detect and
quantify the level of neutralizing activity to IFNB treat-
ment, such as the CPE and the luciferase assay. These
assays differ not only in their sensitivity and specificity
but also in their performance in various laboratories
resulting in differences with respect to NAb detection
and titer quantification [22]. Furthermore, difficulties in
standardizing these assays have considerably hindered
inter-laboratory comparison of NAb data [23].
Here, we assessed the variability and agreement of NAb
testing results between different methods and laboratories
offering routine NAb testing to detect and quantify neu-
tralizing activity to IFNB treatment in clinical practice.
There was a high intra-laboratory agreement for NAb de-
tection and quantification with the MxA induction assay
that was used in the BEYOND trial. This finding reveals a
robust stability of the neutralizing activity in patient sera
stored for several years and a good retest reliability of the
MxA induction assay that was used. With respect to the
inter-laboratory comparisons, there remained high agree-
ment of NAb detection and quantification between the
MxA induction assay and one laboratory using a CPE
assay, with just a systematic difference in titers. This con-
trasted with only moderate agreement between the MxA
assay and the CPE assay used by a second laboratory and
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Figure 2 Intra-laboratory comparison of NAb status and NAb titers at Laboratory A. The titer value of a sample measured in Laboratory A
(II) three years after the end of the study (x-axis) is plotted against the value of a sample measured in Laboratory A (I) shortly after the end of the
study (y-axis). A total of 43 samples tested negative in both laboratory runs. The solid line indicates equal titer levels in both laboratories the
dashed lines indicate the lower limits of quantification.
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Figure 3 Inter-laboratory comparison of neutralizing antibody (NAb) status and NAb titers. The number of samples yielding values below
the lower limit of quantification (LLOQ) in both laboratories is given in the gray boxes. The solid line indicates equal titer levels in both
laboratories. Dashed lines indicate the LLOQs of the respective laboratories.
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two CPE laboratories. Also, the agreement between the
MxA assay and both CPE assays with a luciferase assay
was only moderate. Of note, when comparing individual
titer levels, substantial differences were recorded between
laboratories: we frequently observed that high-titer NAb
positivity was measured by one lab in a sample that was
found to contain low-titer NAb positivity by another lab.
Occasionally, even high-titer NAb positivity was reported
for samples that were tested NAb negative by another la-
boratory using a different method.
The focus of this work was to investigate the differ-
ences in NAb testing and quantification between labora-
tories offering NAb services in clinical practice. More
research is warranted to better understand the observed
discrepancies. This research could constitute the starting
point for further standardization of NAb testing. For in-
stance, higher titers have been observed when IFNB-1a
vs. IFNB-1b was used as the antigen to test neutralizing
activity, a finding that is in line with the somewhat
higher titers of our laboratory D using IFNB-1a in a
Luciferase assay [24]. In light of our findings, results of
NAb testing obtained in different assays/laboratories
must be interpreted or compared with caution. This is of
particular importance when titer thresholds are consid-
ered for clinical decision-making as there are both sys-
tematic shifts and potentially high variability between
test methods and among laboratories. Because high-titer
NAb positivity may be regarded as a sufficient reason to
stop IFNB and switch to a non-IFNB product even if
patients are doing well [21], a false-positive NAb titer
might have disadvantageous therapeutic consequences.
Therefore, our findings underscore the need for global
standardization efforts whenever complex indirect bio-
logical assays are to be used. They also support the
recommendation of NAb experts to supplement testing
for NAbs with more direct measurements of IFNB-
induced biological activity in patients undergoing IFNB
treatment (such as the measurement of MxA induction
following an IFNB injection) [21]. Yet, the predictive
value of measuring IFNB activity needs still to be estab-
lished in a well-designed prospective trial [25].
Conclusion
There are differences in the detection and quantification
of IFNB-1b-induced NAbs between different laboratories
and the assay methods used in clinical practice. It is im-
portant that these differences are considered not only
when interpreting NAb results but also when developing
general recommendations for potentially clinically rele-
vant NAb titer levels.
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